THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL;CANCER RESEARCH TECHNOLOGY LIMITED;ASTEX THERAPEUTICS LIMITED
发明人:
BERDINI, VALERIO,BOYLE, ROBERT GEORGE,SAXTY, GORDON,WALKER, DAVID WINTER,WOODHEAD, STEVEN JOHN,WYATT, PAUL GRAHAM,CALDWELL, JOHN,COLLINS, IAN,DA FONSECA , TATIANA FARIA,DONALD, ALASTAIR
申请号：
ES10184485
公开号：
ES2523266T3
申请日:
2005.10.25
申请国别(地区):
ES
年份:
2014
代理人:
摘要：
A compound for use as a protein kinase B inhibitor, the compound being a compound of formula (I): or salts, solvates, tautomers or N-oxides thereof, where T is N or a CR5 group； J1-J2 represents a group selected from N>； = C (R6), (R7) C>； = N, (R8) NC (O), (R8) 2C-C (O), N>； = N and (R7) C>； = C (R6)； E is a 5 or 6-membered monocyclic carbocyclic or heterocyclic group per ring, where the heterocyclic group contains up to 3 heteroatoms selected from O, N and S, where E is non-aromatic and where the carbocyclic or heterocyclic group is unsubstituted or substituted with one or more R10 substituent groups； Q1 is a bond or a saturated hydrocarbon linker group containing 1 to 3 carbon atoms, where one of the carbon atoms of the linker group may be optionally replaced by an oxygen or nitrogen atom, or a pair of carbon atoms adjacent may be replaced by CONRq or NRqCO, where Rq is hydrogen, (C1-4) alkyl or cyclopropyl, or Rq is an (C1-4) alkylene chain bonded to R1 or another carbon atom of Q1 to form a cyclic moiety； and where the carbon atoms of linker group Q1 may optionally carry one or more substituents selected from fluorine and hydroxy； Q2 is a bond or a saturated hydrocarbon linker group containing 1 to 3 carbon atoms, where one of the carbon atoms of the linker group may be optionally replaced by an oxygen or nitrogen atom； and where the carbon atoms of the linker group may optionally carry one or more substituents selected from fluorine and hydroxy, provided that the hydroxy group, when present, is not located on a carbon atom α with respect to the group G； G is selected from hydrogen, NR2R3, OH and SH； R1 is hydrogen, or an aryl or heteroaryl group, with the proviso that when R1 is hydrogen and G is NR2R3, then Q2 is a bond, where R1 is an aryl or heteroaryl group, and R1 is not substituted or substituted with one or more R10 substituents； R2 and R3 are independently selected from hydrogen, hydrocarbyl (C1-4) and acyl (C1-4), where the hydrocarbyl and acy
